Saku K, Liu K, Takeda Y, Jimi S, Arakawa K
Department of Internal Medicine, Fukuoka, Japan.
Clin Ther. 1995 Nov-Dec;17(6):1136-46. doi: 10.1016/0149-2918(95)80092-1.
The short- and long-term effects of the angiotensin-converting enzyme inhibitor lisinopril and the cardioselective beta-blocker bisoprolol on serum lipids, lipoproteins, apolipoproteins, and lipoprotein(a) (Lp[a]) levels were investigated in patients with mild-to-moderate essential hypertension. Fifty-two patients completed the 12-month, randomized, multicenter trial. After administration of lisinopril (10 to 20 mg/d; n = 24) and bisoprolol (2.5 to 10 mg/d; n = 28), systolic and diastolic blood pressures decreased significantly (P < 0.01) from baseline in both groups at 3, 6, and 12 months. The reduction in diastolic blood pressure was significantly (P < 0.05) greater in the lisinopril group than in the bisoprolol group only at 6 months. Heart rates dropped significantly in the bisoprolol group but not in the lisinopril group. No significant changes in lipids, lipoproteins, apolipoproteins, or Lp(a) levels were observed with either drug at 3, 6, or 12 months, and no significant differences were noted between the two drugs for these parameters. We conclude that lisinopril and bisoprolol are effective as antihypertensive drugs without adverse metabolic effects after short- and long-term treatment in patients with mild-to-moderate essential hypertension.
在轻至中度原发性高血压患者中，研究了血管紧张素转换酶抑制剂赖诺普利和心脏选择性β受体阻滞剂比索洛尔对血脂、脂蛋白、载脂蛋白和脂蛋白(a) [Lp(a)]水平的短期和长期影响。52例患者完成了为期12个月的随机多中心试验。给予赖诺普利（10至20mg/d；n = 24）和比索洛尔（2.5至10mg/d；n = 28）后，两组在3个月、6个月和12个月时收缩压和舒张压均较基线显著降低（P < 0.01）。仅在6个月时，赖诺普利组舒张压的降低幅度显著大于比索洛尔组（P < 0.05）。比索洛尔组心率显著下降，而赖诺普利组未下降。在3个月、6个月或12个月时，两种药物均未观察到血脂、脂蛋白、载脂蛋白或Lp(a)水平的显著变化，且两种药物在这些参数上无显著差异。我们得出结论，在轻至中度原发性高血压患者中，短期和长期治疗后，赖诺普利和比索洛尔作为抗高血压药物有效，且无不良代谢影响。
